Form 4: ADMA Biologics CEO Adam Grossman Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
ADMA Biologics' CEO, Adam Grossman, exercised stock options and sold shares of common stock on April 15, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On April 15, 2025, Adam S. Grossman, the President and CEO of ADMA Biologics, Inc., executed a stock option to acquire 15,000 shares of common stock at a price of $5.40 per share.
- Simultaneously, Grossman sold 15,000 shares at $21.46 per share and an additional 6,000 shares at $21.46 per share.
- These transactions were conducted under a pre-existing Rule 10b5-1 trading plan established on December 5, 2024.
- Following these transactions, Grossman directly owns 2,055,850 shares of ADMA Biologics common stock.
- Grossman also indirectly owns 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC.
- He also holds options to purchase 840,950 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It is common for executives to utilize Rule 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- The transactions do not appear to have any impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2022-03-07 | Grant date of 75,000 unvested RSUs that vest quarterly on each annual anniversary of the date of grant, over four years. |
| 2023-03-06 | Grant date of 286,848 unvested RSUs that vest quarterly on each annual anniversary of the date of grant, over four years. |
| 2024-02-26 | Grant date of 418,296 unvested RSUs that vest quarterly on each annual anniversary of the date of grant, over four years. |
| 2024-02-26 | Grant date of stock option for 15,000 shares, vesting over four years. |
| 2024-12-05 | Date of establishment of Rule 10b5-1 trading plan. |
| 2025-02-19 | Grant date of 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years. |
| 2025-02-26 | 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant |
| 2025-04-15 | Date of stock option exercise and share sales. |
| 2028-02-26 | Stock options become fully vested. |
| 2034-02-26 | Expiration date of stock option. |
Keywords
ADMA Biologics, Adam Grossman, stock options, Rule 10b5-1, insider trading, securities, common stock, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.